Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
21.31
-0.86 (-3.88%)
Jan 28, 2026, 4:00 PM EST - Market closed
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $399.36M in the quarter ending September 30, 2025, a decrease of -14.52%. This brings the company's revenue in the last twelve months to $2.41B, up 47.15% year-over-year. In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth.
Revenue (ttm)
$2.41B
Revenue Growth
+47.15%
P/S Ratio
0.87
Revenue / Employee
$1,759,267
Employees
1,372
Market Cap
2.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | 380.83M | 79.80M | 26.51% |
| Dec 31, 2018 | 301.03M | 146.45M | 94.74% |
| Dec 31, 2017 | 154.58M | 149.16M | 2,751.58% |
| Dec 31, 2016 | 5.42M | 4.17M | 332.64% |
| Dec 31, 2015 | 1.25M | -8.50M | -87.16% |
| Dec 31, 2014 | 9.76M | -4.46M | -31.38% |
| Dec 31, 2013 | 14.22M | -23.11M | -61.91% |
| Dec 31, 2012 | 37.33M | -9.66M | -20.56% |
| Dec 31, 2011 | 46.99M | 17.57M | 59.72% |
| Dec 31, 2010 | 29.42M | 11.84M | 67.30% |
| Dec 31, 2009 | 17.59M | -3.67M | -17.28% |
| Dec 31, 2008 | 21.26M | 10.27M | 93.52% |
| Dec 31, 2007 | 10.99M | 10.87M | 9,428.06% |
| Dec 31, 2006 | 115.29K | -4.67M | -97.59% |
| Dec 31, 2005 | 4.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 630.60M |
| Galapagos NV | 336.64M |
| Wave Life Sciences | 109.23M |
| Ocular Therapeutix | 55.78M |
| Ascentage Pharma Group International | 54.52M |
| Recursion Pharmaceuticals | 43.69M |
| Mesoblast | 17.20M |
| Dianthus Therapeutics | 3.08M |
SRPT News
- 2 days ago - Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript - Seeking Alpha
- 2 days ago - Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys - Barrons
- 2 days ago - Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows - Reuters
- 2 days ago - Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Business Wire
- 5 days ago - Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy - Business Wire
- 12 days ago - Sarepta Therapeutics: Is Elevidys A Bust? - Seeking Alpha
- 16 days ago - Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues - Business Wire